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GRASP65 (Golgi reassembly and stacking protein of 65KDa) is a cis-Golgi protein with roles in Golgi structure, membrane trafﬁcking
andcellsignalling.Itiscleavedbycaspase-3earlyinapoptosis,promotingGolgifragmentation.Wenowshowthatcleavageisneeded
for Fas-mediated apoptosis: expression of caspase-resistant GRASP65 protects cells, whereas expression of membrane proximal
caspase-cleaved GRASP65 fragments dramatically sensitises cells. GRASP65 coordinates passage through the Golgi apparatus of
proteins containing C-terminal hydrophobic motifs, via its tandem PDZ type ‘GRASP’ domains. Fas/CD95 contains a C-terminal
leucine–valinepairingso itstrafﬁckingmightbecoordinatedbyGRASP65. MutagenesisoftheFas/CD95LV motifreducesthenumber
of cells with Golgi-associated Fas/CD95, and generates a receptor that is more effective at inducing apoptosis; however, siRNA-
mediatedsilencingorexpressionofmutantGRASP65constructsdonotalterthesteadystatedistributionofFas/CD95.Wealsoﬁndno
evidence for a GRASP65–Fas/CD95 interaction at the molecular level. Instead, we ﬁnd that the C-terminal fragments of GRASP65
produced following caspase cleavage are targeted to mitochondria, and ectopic expression of these sensitises HeLa cells to Fas
ligand. Our data suggest that GRASP65 cleavage promotes Fas/CD95-mediated apoptosis via release of C-terminal fragments that act
at the mitochondria, and we identify Bcl-XL as a candidate apoptotic binding partner for GRASP65.
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The secretory pathway comprises sequential membrane
compartments that regulate the synthesis, post-translational
processing and targeting of soluble and membrane proteins.
1
Maintaining the correct distribution of lipids and proteins
between the organelles of the secretory pathway is essential
for cellular function. This is achieved through the actions of
vesicular–tubular transport intermediates that trafﬁc between
compartments,andfactorsthatcontrolthefusionofthesewith
acceptor membranes.
1 Data predict that pathways exist to
recognise errors in the secretory pathway function, and to
transduce these signals to apoptotic cell death pathways,
2–5
although the underlying mechanisms are poorly understood.
Strong evidence suggests that the biosynthetic and endo-
cytic pathways are disrupted by caspase activity during
apoptosis
2,6–11; for example, the Golgi apparatus fragments
and scatters throughout the peripheral cytoplasm during
the execution phase following caspase cleavage of many
resident proteins including golgin-160,
9 p115,
10 giantin
8 and
GRASP65.
11 Importantly, caspase-2-mediated cleavage of
golgin-160 has been shown to be necessary for an efﬁcient
apoptotic response in cells challenged with TNFa, TRAIL and
Fas ligand,
12 suggesting that caspase cleavage of Golgi
proteins is a prerequisite for apoptosis in certain contexts.
The Golgi stacking factor, GRASP65, is an important
regulator of Golgi structure and function. It is required for
both the establishment
13 and maintenance
14 of Golgi struc-
tural integrity, it coordinates passage of cargo through the
Golgi,
15–17 and it is implicated in the accurate post-transla-
tional processing of plasma membrane proteins.
14 Properties
associated with the C-terminus of GRASP65 contribute to
growth factor signalling during interphase,
18 and regulate
Golgi reorientation in migrating cells.
19 In addition, CDK1/
cyclin-B-mediated phosphorylation at the C-terminus of
GRASP65 establishes a platform for binding of polo-like
kinase,
20 thereby integrating mitotic kinase signalling with the
timely passage through pro-metaphase.
20–24 These ﬁndings
demonstrate that GRASP65 is an important component of
signalling pathways at the Golgi.
25 GRASP65 structure/
function is altered rapidly and efﬁciently by caspase cleavage
at the early stages of apoptosis.
11 GRASP65 has three
caspase-3 sites within its membrane distal C-terminal signal-
lingdomain.
11We previouslydemonstratedthatexpressionof
caspase-resistant GRASP65 delays apoptotic Golgi fragmen-
tation, but did not examine its wider implications.
11 To
determine whether caspase cleavage of GRASP65 is
important for effective apoptotic signalling, we have examined
the apoptotic responses of cells expressing mutant forms of
GRASP65. We ﬁnd that caspase cleavage of GRASP65 is
needed for apoptosis in cells treated with Fas ligand, and that
cells expressing membrane proximal GRASP65 cleavage
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GRASP65 cleavage contributes to apoptotic signalling via
release of membrane distal caspase cleavage fragments that
translocate to the mitochondria and engage downstream
execution phase processes, and we identify Bcl-XL as a
candidate apoptotic GRASP65 binding partner.
Results
Caspase cleavage of GRASP65 is required for some
forms of apoptosis. Many Golgi proteins are cleaved by
caspases during apoptosis, leading to Golgi disassembly and
arresting membrane trafﬁc.
5,8–12,26–28 We tested whether
caspase cleavage of GRASP65 is required for apoptosis by
measuring cell death (cleaved PARP) in HeLa cell lines
stably expressing wild-type or caspase-resistant GRASP65–
GFP
11 (Figure 1a and b). The rates of apoptosis were similar
between these cell lines under treatment with UV,
anisomycin, TRAIL or TNFa; however, caspase-resistant
GRASP65–GFP cells were more sensitive to staurosporine
(Figure 1b), and were protected from Fas-ligand-induced
apoptosis (Figure 1b and c; Supplementary Video 1). The
differential responses of these cell lines to staurosporine are
still under investigation. In this study, we have focussed on
GRASP65 and the Fas/CD95 pathway, as a further example
Figure 1 Expression of caspase-resistant GRASP65 protects cells from Fas-mediated apoptosis. (a) Fluorescence images of GRASP65 in standard Hela cells (labelled
with GRASP65 antibodies) and HeLa cells stably expressing wild-type or caspase-resistant GRASP65–GFP. Bar¼20mm. (b) Apoptosis responses of standard HeLa cells,
andHeLa cellsstablyexpressingwild-typeor caspase-resistant GRASP65–GFPto variousapoptoticstimuli.Apoptoticcells werescored by immunoﬂuorescencedetectionof
caspase-cleaved PARP. Data show means±S.D. for a minimum of three experiments. Students’ t-test: ***Po0.001, NS, not signiﬁcant. (c) Time-matched frames from time
lapse movies of HeLa cells stably expressing wild-type and caspase-resistant GRASP65–GFP treated with Fas ligand, comparing the rates of apoptosis (rounded, blebbing
proﬁles) between these cell lines (frames correspond to Supplementary Video 1). Bar¼20mm
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Cell Death and Diseaseof how caspase action at the Golgi apparatus propagates cell
death signals from surface receptors.
12
GRASP65 contains three caspase sites within its
C-terminal serine/proline-rich domain (D
320;D
375;D
393 in
rat;
11 Figure 2a). This domain is responsible for Golgi
organisation, but is not required for GRASP65 dimerisation.
29
To examine the roles of the C-terminus of GRASP65 in
Fas/CD95 cell death signalling, we generated HeLa cell lines
stably expressing membrane proximal caspase-cleavage
fragments of GRASP65 fused to mCherry (N320, N375,
N393: Figure 2b and c). These constructs were targeted
normally to the Golgi apparatus (Figure 2c), and the cell
lines showed no morphological or proliferative defects (data
not shown). However, when treated with Fas ligand, cells
expressing the two shortest caspase fragments (N320; N375)
died at dramatically accelerated rates compared with the
wild-type GRASP65–GFP cell line and wild-type GRASP65–
mCherry cells (Figure 2d). Cells expressing the longest form
of caspase-cleaved GRASP65 (N393) were only marginally
sensitised (Figure 2d), suggesting that factors between amino
acids 320 and 393 are responsible. Assessment of the
kinetics of Fas-mediated apoptosis showed that expression
of N320 GRASP65–mCherry accelerated the apoptotic
rate considerably (Figure 2e and f). Similarly, the N320
GRASP65–mCherry cell line was highly sensitised to low
doses of Fas ligand (2h treatment; Figure 2e).
Expression of caspase-resistant golgin-160 protects cells
from the secretory pathway stress.
12 We measured apoptosis
in cells treated with the sarco/endoplasmic reticulum Ca
2þ
ATPase inhibitor, thapsigargin (Figure 2g). Caspase-resistant
GRASP65 reduced apoptosis rates compared with parental
HeLa cells and the wild-type GRASP65–GFP expressing
cell line (although not statistically signiﬁcant; Figure 2g). In
addition, HeLa cells stably expressing N320 GRASP65–
mCherry were sensitised to apoptosis (Figure 2g), pointing
to a general role for GRASP65 cleavage in the secretory
pathway stress and Fas/CD95 signalling.
A C-terminal PDZ-binding motif coordinates Fas/CD95
Golgi retention. Apoptotic Fas/CD95 signalling requires
biosynthetic membrane trafﬁcking. In cells treated with Fas
ligand in the presence of brefeldin A (BFA) apoptotic efﬁciency
was clearly reduced (as judged by immunoblotting with anti-
cleaved PARP antibodies; Figure 3a). Notably, the steady state
levels of Fas/CD95 at the plasma membrane were similar
between mutant GRASP65 cell lines, suggesting that Fas/
CD95 is not retained internally in any of these (Figure 3b).
GRASP65 generates lateral linkages between adjacent Golgi
stacks,
14 a property that is essential for accurate lateral
distribution of enzymes and for efﬁcient sialylation of surface
proteins
14 – an important feature of the functional Fas
receptor.
30 In cells expressing wild-type GRASP65–mCherry
or N320 GRASP65–mCherry, lateral diffusion of the Golgi
enzyme b1,2N-acetylglucosaminyltransferase I (NA–GFP) was
similar (Figure 3c). This suggests that the Golgi apparatus is
intact in N320 GRASP65–mCherry expressing cells (Figure 3c)
– a scenario that differs from cells silenced for GRASP55 or
GM130, which show deﬁciencies in lateral Golgi enzyme
mobility.
14,31
Truncation of 15 amino acids from the C-terminus of Fas/
CD95 sensitises cells to Fas ligand.
32 Fas/CD95 terminates
with a leucine–valine (LV) motif through which it binds to the
tandem PDZ domains of Fas-associated phosphatase, Fap-1
–aninteractionthatisimportantforitsintracellulartargeting.
33
Indeed, overexpression of Fap-1 is a feature of cancers that
show resistance to Fas ligand.
33 At steady state, Fas/CD95
is found at signiﬁcant levels at the Golgi apparatus, and
mobilisation of this Golgi pool is a prerequisite for effective
Fas-mediated apoptosis.
34 Importantly, GRASP65 has been
foundincomplexwithFas/CD95andcaspase-8,
35suggesting
that it might mediate the trafﬁcking of the Fas/CD95
DISC complex. GRASP65 possesses tandem PDZ domains
(Figure 2a), through which it coordinates trafﬁcking of p24
cargo adaptors, TGFa,
15 CD8a and Frizzled4
16 via tandem
C-terminal acidic residues. To test whether GRASP65
interacts with Fas/CD95 and inﬂuences Fas/CD95 bio-
synthetic trafﬁcking, we prepared wild-type and LV-to-AA tail
mutants of Fas/CD95 with luminal/extracellular membrane-
proximal GFP tags (Figure 4a), and compared their sub-
cellular locations and apoptosis-inducing capabilities
(Figure 4b–d). Each construct showed the same distribution
pattern with evidence for cell surface localisation and for a
Golgi pool, and the expression levels of each construct were
similar (Figure 4b and c); however, Golgi-localised Fas–GFP
ﬂuorescence levels were signiﬁcantly greater for wild type
than for tail mutant constructs (Figure 4c). Interestingly, we
found that tail mutant Fas–GFP was released more slowly
from the Golgi than wild-type Fas–GFP (Figure 4d). Despite
this, mutant Fas–GFP was more cytotoxic than its wild-type
counterpart (Figure 4d). Interestingly, in cells expressing
high levels of mutant Fas–GFP, we often observed ﬁlamen-
tous juxtanuclear structures (Figure 4e). These were of
similar dimensions to GRASP65-labelled Golgi membranes
(Figure 4e), but did not co-localise with markers of the Golgi
apparatus, TGN or endocytic compartment (Supplementary
Figure 1), suggesting that they represent a novel compart-
ment exaggerated by the presence of mutant Fas–GFP.
If GRASP65 coordinates Fas/CD95 trafﬁcking, then we
would anticipate a change in the steady state localisation of
Fas/CD95 in GRASP65-suppressed cells; however, the
distribution patterns of wild-type and tail mutant GFP–Fas
were not substantially different in GRASP65-silenced cells
(compare Figure 4b and f). To assess binding between
GRASP65 and Fas/CD95 in vitro, we produced GST-tagged
Fas/CD95 tail constructs (Figure 5a) and used these to probe
HeLa cell lysates.
15 For these experiments, a tail construct of
GM130 was used as a positive control (Figure 5a). We
observed strong binding of GRASP65 to GM130 tail, but only
weak binding to Fas/CD95 tail constructs (Figure 5a).
Signiﬁcantly, we observed no apparent differences between
wild-type and tail mutant Fas/CD95 constructs (Figure 5a).
We next immunoprecipitated GRASP65 and Fas/CD95
from HeLa cell lysates; however, the corresponding candi-
date partner protein was not detected in the bound fractions
(Figure 5b and c). We then transfected HeLa cells with wild-
type or tail mutant Fas–GFP, and subjected cell lysates to
GFP–Trap immunoprecipitation
36 (Figure 5d). In parallel, we
tested lysates from HeLa cells stably expressing wild-type
GRASP65–GFP
11 (Figure 5e). We probed Fas–GFP immune
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Cell Death and DiseaseFigure2 CaspasecleavageofGRASP65sensitisescellstoFasligandandthapsigargin.(a)SchematicofthebasicstructureofGRASP65showingthetwoPDZ‘GRASP’
domainsandserine/proline-richdomaincontainingphosphorylationandcaspasesites.(b)SummaryoftherelativesensitivitiesofthedifferentGRASP65-expressingHeLacell
lines to different apoptotic stimuli. ND, not determined. (c) Fluorescence images of ﬁelds of HeLa cells stably expressing truncated GRASP65 constructs with mCherry tags.
Bar¼10mm. (d) Responses of the cell lines shown to Fas ligand (FasL). N320–mCherry and N375–mCherry cell lines are dramatically sensitised. Data to the left show
means±S.D. for a minimum of three experiments. Students’ t-test compared with wild-type GRASP65–mCherry cells: ***Po0.001, NS, not signiﬁcant. (e) Above, time-
course of apoptosis of the different GRASP65-expressing cell lines treated with Fas ligand (0.1ng/ml). Below, dose responses of the GRASP65 cell lines to Fas ligand (2h
treatment). (f) Immunoblot showing PARP cleavage proﬁles of standard HeLa cells, caspase-resistant GRASP65–GFP cells and N320 GRASP65–mCherry cells. o, Full-
length PARP; oo, caspase-cleaved PARP. (g) Responses of various GRASP65 cell lines to thapsigargin treatment
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GFP immune precipitates with antibodies recognising Fas/
CD95, GM130, and Bcl-2, Bcl-XL and p53 (three candidate
GRASP65 binding partners identiﬁed by antibody array;
Supplementary Figure 2; Figure 5d and e). Although wild-
type Fas–GFP was efﬁciently isolated, we did not detect
GRASP65 in these immune complexes (Figure 5d). Similarly,
GRASP65–GFP isolates were negative for Fas/CD95 and for
caspase-8, although these were enriched for GM130
(Figure 5e). Also, although we were routinely able to clear
the cell lysates of GRASP65–GFP, we never detected Bcl-2,
Bcl-XL or p53 in the GRASP65–GFP complexes (Figure 5e).
Cleavage of GRASP65 is an early event during
apoptosis. To study the timing of GRASP65 cleavage,
and to test whether different inducers of apoptosis promote
cleavage with differing kinetics, we treated wild-type
GRASP65–GFP HeLa cells with Fas ligand, anisomycin, or
TRAIL, and measured Golgi-associated GRASP65–GFP
ﬂuorescence during apoptosis (Figure 6a and b). On
caspase cleavage, GFP is released from membrane-
associated GRASP65–GFP
11 (Figure 6a), providing a
quantitative read-out of GRASP65 cleavage. In Fas ligand
and anisomycin-treated cells the mean time for complete loss
of Golgi-associated GRASP65–GFP was similar (B24min;
Figure 6b), whereas for TRAIL-treated cells, the mean time
was much less (B14min; Figure 6b), possibly reﬂecting
variations in the timing of caspase-3 activation (required for
GRASP65 cleavage
11). Notably, we routinely observed a
decline in Golgi-associated GRASP65–GFP ﬂuorescence
30–40min before apoptotic execution exclusively in the Fas-
ligand-treated cells, suggesting that advanced cleavage of a
pool of GRASP65 might be a feature of Fas-mediated
apoptosis. This implicates caspase-8, the initiator caspase
that acts upstream of caspase-3 in the Fas/CD95 pathway.
We tested cleavage of GRASP65 in vitro using recombinant
caspase-8 (Figure 6c), and compared caspase-8 and Bid
processing in wild-type and mutant GRASP65 cell lines
(Figure 6d). GRASP65 was weakly cleaved by recombinant
caspase-8 (Figure 6c), suggesting that caspase-8 might
contribute to GRASP65 cleavage in living cells. Processing
of caspase-8 was noticeably advanced in the N320
GRASP65–mCherry cell line (Figure 6d), consistent with
the rate of Fas-mediated apoptosis in these cells. Impor-
tantly, caspase-8 processing was very similar between
parental HeLa cells, and wild-type and caspase-resistant
GRASP65–GFP cell–lines (Figure 6d), suggesting that
the protection from Fas-mediated apoptosis afforded by
caspase-resistant GRASP65 arises downstream of caspase-
8 activation. In support of this, the rate of Bid cleavage in
these cell lines was very similar (Figure 6d) implying a
functional Fas/CD95 death receptor/caspase-8 activation
pathway. Importantly, siRNA silencing of Bid expression did
not delay Fas-mediated apoptosis in either wild-type or
caspase-resistant GRASP65–GFP cell lines (Figure 6e),
suggesting that ampliﬁcation of the apoptotic response via
Bid cleavage is not a prerequisite for apoptotic induction
in this context. Together, these data support a role for early
caspase cleavage and release of the C-terminus of
GRASP65 in apoptotic signalling in the Fas/CD95 pathway.
GRASP65 cleavage couples Golgi disruption to
apoptotic nuclear disassembly. The C-terminus of
GRASP65 has a low isoelectric point, which may direct
GRASP65 cleavage products into the nucleus.
24 Surpris-
ingly, wild-type and caspase-resistant GRASP65–GFP
stable cell lines show different apoptotic phenotypes,
supporting a possible nuclear role for GRASP65 caspase
products (Figure 7a–d): apoptotic wild-type GRASP65–GFP
expressing cells had condensed, fragmented and scattered
chromatin, consistent with late stages of nuclear disruption
(Figure 7a and see Lane et al.
11); meanwhile, apoptotic
chromatin was retained within intact nuclei in apoptotic
caspase-resistant GRASP65–GFP cells (Figure 7a). Consis-
tent with this, B30% of 40,6-diamidino-2-phenylindole (DAPI)
ﬂuorescence was found in the peripheral cytoplasm of
apoptotic control and wild-type GRASP65–GFP expressing
HeLa cells, compared with B12% in the caspase-resistant
GRASP65 cell line (Figure 7b). Live-cell imaging of cells
co-expressing GRASP65–GFP and the chromatin marker
Figure 3 Fas/CD95trafﬁckingandGolgiarchitecturein GRASP65 celllines. (a)ImmunoblotofcleavedPARPshowingtheinﬂuenceof BFAandnocodazoletreatmenton
apoptosis in GRASP65 cell lines treated with Fas ligand (FasL; 6h). (b) Immunoblot of total and surface Fas/CD95 following biotinylation enrichment from the GRASP65
expressing cell lines shown. o, Surface Fas/CD95. (c) Fluorescence recovery after photobleaching (FRAP) analysis of Golgi structural integrity in wild-type and N320
GRASP65–mCherry cells. The trace shows the recovery of NAGFPﬂuorescence (%) into the bleached region (hatched box in the exampleimages). Data are means ± S.D.
for wild-type GRASP65–GFP and N320 GRASP65–mCherry of three cells and six cells, respectively
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Cell Death and Diseasehigh-mobility group box 1 (HMGB1)–CFP supported these
observations (Figure 7c and d; Supplementary Videos 2 and
3). These results are reminiscent of the effects of inhibition of
actin/myosin II upon apoptotic cell remodelling,
37 and indeed
inhibition of myosin II activation (using the ROCK inhibitor,
Y27632) or myosin II contractility (using blebbistatin), or
prevention of nuclear envelope disruption (using the
caspase-6 inhibitor, zVEID.FMK) reduced the peripheral
Figure 4 The C-terminus of Fas/CD95 mediates trafﬁcking through the Golgi apparatus. (a) Schematic of the Fas/CD95 constructs used (CR, coiled coil region).
(b)FluorescenceimagesofFas–GFPtransientlyexpressedinHeLacells.TheGolgiwaslabelledwithGRASP65antibodies.Bar¼20mm.(c)Quantitationoftotalcellularand
Golgi-associated wild-type and tail mutant Fas–GFP measured by ﬂuorescence microscopy (arbitrary units). **Po0.01; NS, not signiﬁcant. (d) Analysis of the proportion of
cells with Golgi-associated Fas–GFP (above) and the rate of cell death (below) in response to cycloheximide (CHX) in the absence (right) and presence (left) of Fas ligand, in
cells expressing wild-type of tail mutant Fas–GFP.Data showmeans ± S.D. for three experiments.(e) Analysisof thedistributionof tail mutant Fas–GFPin HeLa cells.Note
the tubular structures that lie adjacent to, but do not overlap with GRASP65 staining. Further examples of co-localisation with cellular compartments are shown in
SupplementaryFigure1.Bar¼20mm(5mm inzoom).(f)Effectof GRASP65 silencingonGolgi-associated Fas/CD95.ImmunoblotshowingefﬁciencyofGRASP65silencing
with two oligonucleotides (UTR1, untranslated region 1), and examples images of wild-type and tail mutant Fas–GFP in a GRASP65 silencing background. Bar¼10mm
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Cell Death and Diseaseredistribution of chromatin in apoptotic wild-type GRASP65–
GFP cells to a similar extent (Figure 7b).
To examine whether C-terminal GRASP65 cleavage
products accumulate in the nucleus, we transfected cells
with myc- or GFP-tagged C-terminal constructs (designated
DN320, DN375, DN393). These were targeted to the
cytoplasm and were not cytotoxic (data not shown; see
below). To examine whether targeting these constructs to the
nucleus would induce cytotoxicity, we inserted a tripartite
nuclear localisation signal (NLS) upstream of the C-terminus
of GRASP65 (Figure 7e).
38 Each of the C-terminal fragments
accumulated in the nucleus as expected without triggering
obvious changes in nuclear organisation (Figure 7e), and
none were cytotoxic (data not shown). We then treated HeLa
cells transiently expressing these constructs with Fas ligand,
anisomycin or thapsigargin, and monitored apoptosis rates
(Figure 7f–h). None of the NLS-tagged constructs sensitised
cells to apoptosis above the levels observed in NLS–GFP
expressing control cells (Figure 7f–h). These data argue
against a direct role for nuclear targeting of C-terminal
GRASP65 caspase cleavage products in downstream apop-
totic signalling.
GRASP65 caspase cleavage products co-localise with
mitochondria and sensitise cells to Fas ligand and
mitochondrial poisons. On close inspection of the
localisation of epitope-tagged GRASP65 C-terminal
caspase products overexpressed in viable HeLa cells, a
punctate/reticular cytoplasmic pattern was evident. Co-
localisation with markers for mitochondria (e.g., HSP60)
demonstrated that these fragments were targeted to the
mitochondrial network (Figure 8a–c; Supplementary Figure 3).
Mitochondrial co-localisation was seen for myc-tagged
DN320 and DN375 (Figure 8a and b), but was not observed
with myc-tagged DN393 (data not shown), suggesting that the
presumed mitochondrial-targeting domain resides between
Figure 5 GRASP65 and Fas/CD95 do not directly interact at the Golgi apparatus. (a) GST-tail pull-down assay. Comparison of the C-terminal sequence of GM130 – a
protein known to interact with GRASP65 – and the fusion proteins used in the assay (above). Example tail-binding assay showing strong binding of GRASP65 to the
C-terminus of GM130, but only weak binding to both wild-type and mutant tail fusions of Fas/CD95 (below). (b and c) Immunoprecipitation of endogenous Fas/CD95 (b) and
GRASP65(c)andimmunoblottingfortherespectivecandidatebindingpartner.(dande)GFP–TrapimmunoprecipitationsofHeLacellstransientlyexpressingwild-typeortail
mutant Fas–GFP (d), and GFP–Trap immunoprecipitations of HeLa cells stably expressing GRASP65–GFP (e) immunoblotted using the antibodies shown. o, Endogenous
Fas/CD95 or GRASP65; oo, GFP-tagged Fas/CD95 or GRASP65
GRASP65 and apoptotic signalling at the Golgi
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Cell Death and Diseasethe GRASP65 caspase sites (i.e., between amino acids 320
and 393). This is consistent with the Fas/CD95 cytotoxicity
assays in the various GRASP65 truncation mutant cell lines
(Figure 2d). Importantly, we also observed mitochondrial co-
localisation in cells expressing GFP–DN320 (Figure 8c).
One possible outcome of the association of the C-terminus
of GRASP65 with mitochondria is to damage the outer
membrane, leading to release of apoptotic factors and
ensuing cell death. To test this, we transiently transfected
cytochrome c–GFP expressing HeLa cells
39 with N320
GRASP65–myc or DN320 GRASP65–myc, and labelled ﬁxed
cells with anti-myc antibodies (Figure 8d). Cells expressing
DN320 GRASP65–myc showed no evidence of dislocation
of cytochrome c–GFP (Figure 8d), making it unlikely that
the presence of caspase cleavage products of GRASP65 at
the mitochondria causes release of pro-apoptotic factors.
Figure 6 GRASP65 cleavage is an early event during apoptosis. (a) Time-lapse imaging of GRASP65–GFP caspase cleavage. To the top, phase contrast images of a
TRAIL-treated HeLa cell before and after the onset of apoptosis; to the bottom, ﬂuorescence images of Golgi-associated GRASP65–GFP and the loss of GFP signal from the
Golgi following the onset of apoptosis. (b) Normalised ﬂuorescence intensity traces of Golgi-associated GRASP65–GFP in HeLa cells treated with the apoptosis-inducing
reagents shown. Traces are plotted relative to the onset of cell rounding (hatched boxes). Data show means ± S.D. for a minimum of ﬁve cells per treatment.
(c) Autoradiographs of
35S-labelled GRASP65 translated in vitro and incubated for 90min with increasing concentrations of recombinant caspase-3 or caspase-8. Full-length
(o)andcaspase-cleaved(oo)GRASP65productsareshown.(d)ImmunoblotofdifferentcelllinestreatedwithFasligand.Full-lengthcaspase-8(o);processedcaspase-
8( oo). (e) Inﬂuence of Bid silencing on Fas-mediated apoptosis in wild-type and caspase-resistant GRASP65–GFP cell lines. To the left, immunoblot of HeLa cells treated
with silencing oligonucleotides against Bid. To the right, immunoblot comparing levels of cleaved PARP in Fas ligand-treated cells (as shown) silenced or not with a
combination of Bid oligonucleotides 1 and 2
Figure 7 Caspase cleavage of GRASP65 is required for effective apoptotic nuclear disruption. (a) Fluorescence images of wild-type and caspase-resistant GRASP65–
GFP stable HeLa cells treated with anisomycin (6h) and stained with anti-caspase-cleaved PARP antibodies and DAPI. (4) cells undergoing apoptosis; (*) a wild-type
GRASP65–GFP expressing cell at a very early stage of apoptosis with Golgi-associated GRASP65–GFP ﬂuorescence still apparent. Bar¼10mm. (b) Analysis of apoptotic
chromatin redistribution. To the left, DAPI images of example apoptotic nuclei from HeLa cells stably expressing wild-type or caspase-resistant GRASP65–GFP. To the right,
quantitation of DAPI ﬂuorescence in the periphery of apoptotic HeLa cells in the absence or presence of Y27632 (ROCKI inhibitor: 100mM), blebbistatin (myosin II inhibitor:
12.5mM) or zVEID.FMK (caspase-6 inhibitor: 12.5mM). Data show means±S.D. for 30 cells per treatment. Student’s t-test: ***Po0.001. (c and d) Fluorescence time-lapse
imaging of apoptotic cell re-organisation in HeLa cells stably expressing wild-type (c) or caspase-resistant (d) GRASP65–GFP. Cells were transiently transfected with
HMGB1–CFP to label the nuclei. Bar¼10mm. (e–h) Nuclear targeting of GRASP65 caspase products does not sensitise cells to apoptosis. (e) Schematic of the constructs
used in these experiments and example images of NLS- and GFP-tagged GRASP65 caspase products. Cells were co-stained with anti-GRASP65 antibodies and DAPI.
Bar¼10mm. (f–h) Quantitation of apoptosis in HeLa cells transiently expressing NLS–GFP or NLS-tagged GRASP65 caspase products, treated with the apoptosis-inducing
reagents as shown
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Cell Death and DiseaseConsistent with this observation, mitochondrial-associated
GRASP65 DN320 and DN375 caspase cleavage fragments
were not toxic when overexpressed in HeLa cells (data not
shown). Interestingly, though, expression of GRASP65
DN320 and DN375 caspase cleavage fragments signiﬁcantly
sensitised HeLa cells to Fas ligand (Figure 8e), suggesting
that the release of the C-terminus of GRASP65 from the Golgi
apparatus promotes Fas-mediated apoptosis (note that for
these experiments, we used Golgi-targeted GRASP65 N320–
myc as a control, having conﬁrmed that this construct did
GRASP65 and apoptotic signalling at the Golgi
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Cell Death and Diseasenot potentiate the apoptosis response when transiently
expressed; Figure 8e and data not shown).
Although mitochondrial association of the C-terminus of
GRASP65wasnotsufﬁcienttocausereleaseofcytochromec
(Figure 8d), its capacity to sensitise cells to Fas ligand
(Figure 8e) indicated that mitochondrial physiology might
nevertheless be compromised. To explore this, we generated
HeLa cell lines stably expressing GFP or GFP–DN320
GRASP65 by lentiviral transduction and loaded these cell
lines with mitotracker red for imaging using identical acquisi-
tion parameters. Mitochondrial ﬂuorescence was consistently
lower in the GFP–DN320 GRASP65 cells (Figure 8f). We
next subjected these cell lines to the mitochondrial
poisons carbonyl cyanide 3-chlorophenylhydrazone (CCCP)
and antimycin A (Figure 8g). Strikingly, the GFP–DN320
GRASP65 cells were highly sensitised to both CCCP and
antimycin A, although GFP and GFP–DN320 GRASP65 cells
died at similar rates upon treatment with anisomycin
(Figure 8g). Together these observations suggest that
C-terminal GRASP65 caspase cleavage products lower
mitochondrial membrane potential rendering cells more
sensitive to mitochondrial poisons such as CCCP and
antimycin A, and to Fas ligand.
GRASP65 interacts with Bcl-XL during Fas/CD95-
mediated apoptotic commitment signalling. It has
previously been reported that Bcl-XL inﬂuences the
relationships between GRASP65 and the Fas/CD95 disc
complex.
35 We therefore explored the possibility that
GRASP65 interacts with Bcl-XL in viable cells and in cells
primed to undergo apoptosis (i.e. during apoptotic commit-
ment signalling; Figure 8h). We immunoprecipitated
endogenous GRASP65 from untreated HeLa cell lysates
and from lysates of HeLa cells treated whether with
anisomycin or with Fas ligand for 3h in the presence of
zVAD.FMK (Figure 8h). This regime of treatments was
established to enrich for cells arrested during the apoptotic
commitment signalling phase, in which caspase cleavage of
targets, such as GRASP65, had been prevented. GRASP65
bound very weakly to Bcl-XL in untreated cells and in cells
treated with anisomycin (Figure 8h); however, in cells treated
with Fas ligand, robust binding to Bcl-XL was observed
(Figure 8h). This suggests that GRASP65 and Bcl-XL interact
speciﬁcally during the commitment signalling phase of
Fas/CD95-mediated apoptosis, providing a plausible
mechanistic explanation for the inﬂuence of GRASP65
caspase cleavage on the susceptibility of cells to Fas ligand.
Discussion
GRASP65 is an important structural component of the Golgi
apparatus with additional roles in membrane trafﬁcking and
cell signalling. In this study, we have shown that caspase
cleavage of GRASP65 is needed for Fas/CD95 and thapsi-
gargin-mediated apoptosis. A relationship between secretory
pathway dysfunction, caspase cleavage of Golgi residents
and effective apoptotic execution has previously been
suggested for both golgin-160
9,12,27,28 and for p115,
10
indicative of a common theme. How caspase cleavage of
these proteins is coupled to efﬁcient apoptotic progression
remains uncertain. Being an important regulator of Golgi
architecture
11,13,14,29,31 and membrane trafﬁcking,
15,16,40
we initially predicted that GRASP65 cleavage would alter
Fas/CD95 trafﬁcking through the secretory and/or endo-
cytic pathways, thereby affecting the cell-death-inducing
capability of the Fas/CD95 population. Published evidence
for a biochemical interaction between GRASP65 and
Fas/CD95,
35 and the presence of a C-terminal LV motif in
Fas/CD95 (potentially able to bind to the tandem PDZ
domains of GRASP65
15,16), supported this; however,
although the C-terminus of Fas/CD95 coordinates its reten-
tion at the Golgi, we have been unable to obtain data to
conﬁrm this hypothesis. Instead, our results imply that
GRASP65 inﬂuences apoptosis via release of C-terminal
caspase cleavage fragments that translocate to mitochondria
and sensitise cells to Fas/CD95-mediated apoptosis.
Importantly, our data suggest that GRASP65 binds to Bcl-XL
speciﬁcally during apoptotic commitment, suggesting a
molecular pathway linking caspase action at the Golgi
apparatus and the engagement of mitochondrial apoptosis
signalling pathways.
The C-terminus of GRASP65 has a low isoelectric point
suggested to be sufﬁcient to drive caspase cleavage products
into the nucleus.
29 Independent studies have demonstrated
this for p115 and golgin-160.
10,28 In the case of p115, this is
thought to amplify the apoptotic response, because ectopic
expressionofthis fragmentwascytotoxic.
10 Weexaminedthe
potential for GRASP65 caspase fragments to translocate to
the nucleus and inﬂuence apoptotic initiation; however, none
of the C-terminal GFP- or myc-tagged cDNA constructs
representing the three membrane distal caspase fragments
Figure 8 GRASP65 caspase cleavage products are targeted to mitochondria and potentiate Fas-mediated apoptosis. (a, b) Immunoﬂuorescence imaging of HeLa cells
transiently expressing N320 GRASP65–myc or DN320 GRASP65–myc (a), or N375 GRASP65–myc or DN375 GRASP65–myc (b), stained with anti-myc antibodies, anti-
HSP60 and DAPI. Bars¼10mm. (c) HeLa cells transiently expressing GFP–DN320, co-stained with anti-GRASP65 or anti-HSP60 antibodies and DAPI. Bar¼10mm.
(d) Immunoﬂuorescence images of cells HeLa cells stably expressing cytochrome c-GFP and transiently transfected with N320 GRASP65–myc or DN320 GRASP65–myc.
Mitochondrial DN320 GRASP65–myc does not cause release of cytochrome c.( e) Transient expression of DN320–myc or DN375–myc sensitises cells to Fas-mediated
apoptosis(2htreatment).ApoptosiswasassessedusingcleavedPARPantibody.*Po0.05;**Po0.01.(f)TheC-terminusofGRASP65inﬂuencesmitochondrialmembrane
potential. HeLa cells stably expressing GFP or GFP–DN320 GRASP65 were loaded with mitotracker red (15min) then imaged using identical parameters (5ms exposure).
AggregateﬂuorescenceintensitiesforB120cellswereobtained.(g)TheC-terminusofGRASP65sensitisescellstoapoptosismediatedbymitochondrialpoisons.HeLacells
stablyexpressingGFPorGFP–DN320GRASP65weretreatedwiththemitochondrialpoisonsCCCP(29h)andantimycinA(29h),orwithanisomycin(6h),andassessedfor
celldeathbyDAPI staining(condensedand/or pyknoticnuclei).Datashowmeansof threeindependentexperiments.*Po0.05;**Po0.01;NS,notsigniﬁcant. (h)GRASP65
binds to Bcl-XL during apoptotic commitment signalling after Fas ligand treatment. GRASP65 immunoprecipitation of untreated (to the left) and anisomycin or Fas ligand
treated HeLa cells (to the right). Weak binding to Bcl-XL is observed in untreated and in anisomycin treated cells; however, robust Bcl-XL binding is observed in Fas-ligand-
treated cells. Anisomycin and Fas ligand treated cells were treated with zVAD.FMK to prevent caspase activation and GRASP65 cleavage. (arrow, GRASP65 and Bcl-XL;
asterisk, antibody heavy and light chains.)
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cells. Meanwhile, targeting of these fragments to the nucleus
by insertion of a NLS did not decrease the viability of cells
either in the absence or presence of apoptotic stimuli.
Although these data suggest that GRASP65 caspase
products do not inﬂuence events in the nucleus, caspase-
resistant GRASP65–GFP cells show a marked reduction in
chromatin redistribution into the peripheral cytoplasm. This is
reminiscent of the inﬂuence of actin/myosin II inhibitors on the
execution phase
37 (see Figure 7b), implying a direct role for
GRASP65 cleavage either in activating actin/myosin II
contractility, in destabilising the nuclear envelope to facilitate
chromatinrelease,orviaa kineticdelayinapoptotic execution
– the most likely scenario given the resistance to Fas ligand of
cells stably expressing caspase-resistant GRASP65.
The two longest C-terminal GRASP65 caspase fragments
(DN320; DN375) associate with mitochondria and sensitise
HeLacellstoFasligand.Thissuggeststhat GRASP65caspase
products might inﬂuence cell viability via ampliﬁcation of
apoptotic signalling pathways at the mitochondria. We have
used proteomics, yeast two-hybrid analyses and antibody array
screens to identify GRASP65 interactors. Several candidates
wereidentiﬁedintheantibodyarrays,butnoneofthesecouldbe
veriﬁed in our immunoprecipitation experiments of healthy cells.
Our observations that cells over-expressing the longer
C-terminal GRASP65 cleavage products were viable but
became more susceptible to Fas ligand suggested that any
potential interactions between GRASP65 and its candidate
apoptotic binding partners might develop during the apoptotic
commitment phase. We therefore re-examined the potential for
GRASP65 to bind apoptotic factors during apoptotic commit-
ment signalling. Importantly, we found that GRASP65
co-precipitates with Bcl-XL in cells primed to undergo apoptosis
induced by Fas ligand, but not in viable cells or cellstreated with
anisomycin. This suggests that during Fas/CD95 signalling,
Bcl-XL may be recruited to the Golgi via its association with
GRASP65. A model in which Golgi recruitment of Bcl-XL during
Fas/CD95signallinghasacytoprotectiveaffectthatisalleviated
by early caspase cleavage of GRASP65 is a possibility. In cells
expressing caspase-resistant GRASP65, Bcl-XL association
with the Golgi apparatus is prolonged, whereas the occupation
of the Golgi apparatus by over-expressed truncated GRASP65
restricts the recruitment of Bcl-XL to the Golgi. Further
investigations of the possible roles of Bcl-XL at the Golgi, and
the molecular function of the C-terminus of GRASP65 at the
mitochondria will be required to fully understand the linkages
between secretory pathway function and apoptotic signalling.
Materials and Methods
Reagentsandantibodies. Unlessotherwisestated,reagentswereobtained
from Sigma (Poole, UK). Stock solutions of anisomycin (5mg/ml), staurosporine
(1mM), DAPI (1mg/ml), Fas ligand (soluble, FLAG tagged, Alexis Biochemicals,
Exeter, UK: 0.1mg/ml), TNFa (R&D Systems, Abingdon, UK: 100mg/ml),
nocodazole (5mg/ml), thapsigargin (Calbiochem, Nottingham, UK: 5mg/ml), BFA
(Calbiochem: 5mg/ml), Y27632 (Calbiochem: 100mM), blebbistatin (Calbiochem:
100mM), zVEID.FMK (Calbiochem: 12.5mM) were stored at  201C. Stock
solutions of TRAIL (Calbiochem: 20mg/ml) were stored at  801C. Cell surface
proteins were isolated and puriﬁed using a surface biotinylation kit (Pierce,
Loughborough, UK) according to the manufacturer’s instructions. The sheep
anti-human GRASP65 antibody was raised against a recombinant GST fusion of
human GRASP65 (amino acids 201-end), and afﬁnity puriﬁed against His-tagged,
recombinant full-length human GRASP65. The following antibodies were also used:
monoclonal anti-PARP (Calbiochem), polyclonal anti-cleaved PARP (Promega,
Southampton, UK), anti-caspase-8 (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA),anti-Bid(BDBiosciences,Oxford,UK),anti-p53(Upstate,Watford,UK),anti-Bcl-
2 (Upstate), anti-Bcl-XL (Santa Cruz), anti-CD99 was a gift from Professor George
Banting (Bristol, UK), anti-GFP (Covance, Princetown, NJ, USA), anti-a-tubulin (clone
B-5-1-2), anti-acetylated a-tubulin (clone 6-11B-1), anti-TGN46 (AbD Serotec),
anti-giantin (Covance), anti-GM130 (BD Biosciences), anti-b-COP (MAD; a gift from
Professor Viki Allan, Manchester, UK), anti-ERGIC53 (Alexis Biochemicals), anti-
calnexin (Stressgen, Exeter, UK), anti-EEA-1 (BD Biosciences), anti-transferrin
receptor (Sigma), monoclonal anti-Fas (clone CH11; Upstate), polyclonal anti-Fas
(Santa Cruz), anti-HSP60 (Sigma), anti-FLAG (M2; Sigma), anti-myc (clone 9E10;
Sigma). Secondary antibodies for immunoﬂuorescence (Alexa-488 and Alexa-594)
were from Molecular Probes (Paisley, UK). HRP-tagged secondary antibodies were
from Jackson Immunoresearch (Newmarket, UK).
Cell lines and apoptosis induction. Cells were maintained in DMEM
containing 10% foetal bovine serum, at 371C and 5% CO2.H e L ac e l ll i n e ss t a b l y
expressing wild-type and caspase-resistant GRASP65–GFP have been described
previously.
11 HeLa cells stably expressing wild-type and caspase-resistant
GRASP65–mCherry, and mCherry fusions of GRASP65 C-terminal truncations
(N320, N375, N393) were obtained following transient transfection by selecting
positive clones after G418 treatment.
11,37 HeLa cells stably expressing GFP or
GFP–DN320 GRASP65 were prepared by lentiviral trasduction (Lenti-X expression
system; Clontech, Mountain View, CA, USA) and antibiotic selection. Cytochrome c-
GFP stable HeLa cells
39 were kindly provided by Professor Doug Green (St Jude
Children’sResearchHospital,Memphis,TN,USA).Cellswereinducedintoapoptosis
by treatment with 5mg/ml anisomycin, UV irradiation (100J/m
2, Lane et al.
11), 1mM
staurosporine, 20ng/ml TRAIL (with 10mg/ml cycloheximide), 100ng/ml TNFa (with
10mg/ml cycloheximide), 10mMC C C P ;1 mg/ml antimycin A. For Fas-mediated
apoptosisassays,cellsweretreatedwithFLAG-tagged,solubleFasligand(0.1mg/ml)
in the presence of 0.5mg/ml anti-FLAG monoclonal antibody and 10mg/ml
cycloheximide. Cells were then incubated for the indicated times at 371C, 5% CO2.
cDNAconstructsandtransfections. ThehumanHMGB1–CFPconstruct
has been described previously.
6 Plasmid pCNG2 encoding a GFP fusion of the ﬁrst
103 amino acids of NA–GFP was a gift from Professor Viki Allan (Manchester, UK).
C-terminal CFP and YFP fusions of GRASP65 were made by colour switching the
GRASP65–GFP construct. GRASP65–mCherry was made by PCR amplifying the
mCherry sequence (a gift from Roger Tsien), and sub-cloning into GRASP65–GFP
to replace GFP (the BamHI site in the rat GRASP65 ORF was ﬁrst altered by site-
directed mutagenesis). C-terminal GFP fusions of caspase-cleavage-mimicking
truncations of GRASP65 (N320, N375, N393) were prepared by PCR ampliﬁcation
of the appropriate domains using caspase-resistant GRASP65–GFP as a template
(hence all caspase sites within these constructs are mutated (D to A);
11). These
were then colour switched with mCherry (as described above). Nuclear-targeted
GRASP65 constructs were prepared by inserting a tripartite nuclear localisation
signal (see Moss et al.
38) upstream of the C-terminal GRASP65 caspase-cleaved
products in pEGFP (DN320, DN375, DN393–NLS–GFP). GFP- and myc-tagged
GRASP65 C-terminal caspase products were prepared by PCR ampliﬁcation and
insertionintopEGFPandpcDNA3.1myc/his(Invitrogen,Paisley,UK),respectively.
The GFP-Fas construct was prepared by insertion of GFP at an internal BamHI site
upstreamof the transmembrane domainof humanCD95/Fas. GST-C-tail fusions of
GM130andFaswerepreparedbyinsertingannealedoligonucleotidesencodingthe
relevant coding regions downstream of the GST open reading frame.
15 Cytokeratin
8-GFP was a gift from Professor Viki Allan (Manchester, UK). mCherry–Rab7a and
Rab9a were gifts from Professor Pete Cullen (Bristol, UK). All constructs were
veriﬁed by sequencing. Transient transfections were carried out using Fugene 6
(Roche, Lewes, UK) or GeneJuice (Novagen, Nottingham, UK) according to the
manufacturers’ instructions.
Fluorescence microscopy and live cell imaging. Wide-ﬁeld
ﬂuorescence images were obtained using an Olympus (Southend-on-Sea, UK)
IX-71 inverted microscope (60  Uplan Fluorite objective 0.65–1.25 NA, at
maximum aperture) ﬁtted with a CoolSNAP HQ CCD camera (Photometrics,
Tucson, AZ, USA) driven by MetaMorph software (Universal Imaging Corporation,
Downington, PA, USA). Confocal images were obtained using a Leica (Milton
Keynes, UK) AOBS SP2 microscope (63  PLAPO objective 1.4 NA) at 0.2mm
z-steps. For immunoﬂuorescence, cells were ﬁxed in 2% formaldehyde (methanol
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Triton X-100, or in  201C methanol. Cells were routinely stained with DAPI and
mounted in mowiol containing 25mg/ml DABCO anti-fade.
Live-cellimagingwascarriedoutusingtheOlympusIX-71system.Halogenlamp
illuminationwasusedforbothtransmittedlightandforepiﬂuorescencetoextendcell
viability (e.g., Moss et al.
38). Cells were maintained in CO2-independent DMEM
(Invitrogen), at 371C in 3cm cell imaging dishes (MatTek Co, Ashland, MA, USA).
Calculations of the intensity of Golgi-associated GRASP65 signal was carried out
by image thresholding GRASP65-GFP ﬂuorescence using MetaMorph software.
FluorescencelevelswerethenplottedasafunctionofthemaximalGolgiﬂuorescence
value (pre-cell rounding) from the thresholded image data. FRAP investigations of
Golgi enzyme lateral mobility were carried out in cells stably expressing wild-type or
N320GRASP65–mCherry,transientlytransfectedwithNA–GFP,usingaLeicaAOBS
SP2 confocal microscope (as described in Moss et al.
37).
siRNA-mediated silencing. For siRNA silencing, the following
oligonucleotides were used: for GRASP65, G651 – AGGCACUACUGAAAGC
CAAAUTT and UTR1 – GGAAUGCAGCAAGUAGAACAGAAUCGC directed at the
translated and untranslated regions of GRASP65, respectively; for Bid, GAA
GACAUCAUCCGGAAUATT and GAAUAGAGGCAGAUUCUGATT. Oligonucleo-
tides were transfected using Oligofectamine (Invitrogen; manufacturer’s
instructions) or by calcium phosphate at ﬁnal concentrations of 100 and 20nM,
respectively. For calcium phosphate transfections, oligonucleotides (100nM ﬁnal)
were added directly to 250mM CaCl2, and supplemented with an equal volume of
BBS (50mM BES pH 6.95, 280mM NaCl, 1.5mM Na2HPO4). The mixture was
incubatedatroomtemperaturefor20minthenaddeddrop-wisetoB30%conﬂuent
cells in DMEM. These were incubated overnight in 3% CO2 at 371C, before
washing, addition of standard DMEM and incubation at 5% CO2,3 7 1C for 72h.
Antibody array and in vitro caspase assays. The apoptosis antibody
array was from Hypromatrix (Worcester, MA, USA), and was used according to
the manufacturer’s instructions. HRP-tagged anti-GRASP65 was prepared by
covalently attaching HRP to the sheep GRASP65 polyclonal according to the
manufacturer’s instructions (Thermo Scientiﬁc). In vitro caspase cleavage of
GRASP65 was carried out using
35S-labelled, in vitro translated GRASP65 and
recombinant caspase-3 and caspase-8 (Alexis Biochemicals) as described in Lane
et al.
11 Products were incubated in caspase buffer (0.1% CHAPS, 10% sucrose,
5mM DTT, 2mM EDTA, 50mM Hepes, pH 7.4) for 90min at 301C and run on
SDS-PAGE gels for autoradiography.
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